Archive for July 4th, 2009
Resistant Escherichia coli—We Are What We Eat
Clinical Infectious Diseases 15 July 2009 V.49 N.2 p.202–204
EDITORIAL COMMENTARY
Peter Collignon
Infectious Diseases Unit and Microbiology Department, The Canberra Hospital, and School of Clinical Medicine, Australian National University, Canberra, Australia
Full Text
http://www.journals.uchicago.edu/doi/full/10.1086/599831
Add comment July 4, 2009
Emergence of Extended-Spectrum β-Lactamase–Producing Escherichia coli in Community Hospitals throughout North Carolina: A Harbinger of a Wider Problem in the United States?
Clinical Infectious Diseases 15 July 2009 V.49 N.2 p.e30–e32
BRIEF REPORT
Joshua T. Freeman, Daniel J. Sexton, and Deverick J. Anderson
Duke Infection Control Outreach Network, Duke University Medical Center, Durham, North Carolina
Community-onset urinary tract infections due to extended-spectrum β-lactamase–producing Escherichia coli have become increasingly common worldwide but have been considered to be uncommon infections in the United States. We report the emergence and subsequent rapid increase in the incidence of these infections in community hospitals throughout North Carolina since 2006.
abstract
http://www.journals.uchicago.edu/doi/abs/10.1086/600046
Add comment July 4, 2009
Invasive Pneumococcal Disease among Adults: Associations among Serotypes, Disease Characteristics, and Outcome
Clinical Infectious Diseases 15 July 2009 V.49 N.2 p.e23e29
Angelique G. S. C. Jansen,1 Gerwin D. Rodenburg,1 Arie van der Ende,3 Loek van Alphen,4 Reinier H. Veenhoven,5 Lodewijk Spanjaard,3 Elisabeth A. M. Sanders,1 and Eelko Hak1,2,6
1Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital, and 2Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 3Academic Medical Center Amsterdam, Center for Infection and Immunity Amsterdam, Department of Medical Microbiology, and the Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, 4Netherlands Vaccine Institute, Bilthoven, 5Department of Pediatrics, Spaarne Hospital, Hoofddorp, and 6Department of Epidemiology, University Medical Center Groningen, Groningen, the Netherlands
Background. The Streptococcus pneumoniae polysaccharide capsule may be related to invasive pneumococcal disease (IPD) course.
Methods. We performed a retrospective cohort study with nationally representative surveillance data from 1075 hospitalized patients with IPD from the Netherlands from 1 June 2004 through 31 May 2006 in the prevaccination era. Serotypes were grouped according to invasive disease potential, rate of the most serious clinical syndromes of meningitis and bacteremia without focus, and case-fatality rates. Multivariable logistic regression analysis was performed to obtain odds ratios adjusted for baseline confounders for the association of serotypes and these outcomes, using the serotypes with the lowest rates as reference.
Results. IPD caused by serogroups with low invasive disease potential concerned meningitis or bacteremia without focus in 22% of cases, and 74% of patients had an underlying comorbidity. For highly invasive serogroups these figures were 10% ( ) and 56% ( ). Individual serotypes varied in the relative rate by which they caused meningitis or bacteremia without focus. Compared with the reference group composed of serotypes 1, 5, 7F, 15B, 20, and 33F, the group of serotypes 3, 19F, 23A, 16F, 6B, 9N, and 18C was associated with increased case-fatality rates (group adjusted odds ratio, 2.6; 95% confidence interval, 1.5–4.7).
Conclusions. The serotype appeared to be independently associated with IPD severity in adults, which indicates that careful monitoring of IPD after implementation of conjugate vaccines is necessary.
abstract
http://www.journals.uchicago.edu/doi/abs/10.1086/600045
Add comment July 4, 2009
